HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
160:@0.078769:0.033217:0.109813:0.033217:0.109813:0.013052:0.078769:0.013052:0.010348:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
100 cells/mm  who were initiating ART less than a month :@0.076190:0.084931:0.485155:0.084931:0.485155:0.069149:0.076190:0.069149:0.008376:0.008376:0.008376:0.003931:0.009782:0.009827:0.003024:0.003024:0.005866:0.006607:0.014182:0.014182:0.004863:0.003916:0.012564:0.009223:0.009903:0.003916:0.012564:0.009827:0.004551:0.009827:0.003916:0.003024:0.009223:0.003024:0.005125:0.003024:0.010326:0.005125:0.003024:0.009223:0.010175:0.003916:0.011188:0.009177:0.006441:0.003916:0.003024:0.009827:0.005866:0.005866:0.003931:0.005125:0.009223:0.010326:0.009223:0.003916:0.010326:0.003916:0.014182:0.009903:0.009223:0.005125:0.009223:0.004188
3:@0.171746:0.079633:0.176604:0.079633:0.176604:0.070479:0.171746:0.070479:0.004858
after having commenced TB treatment.  The aim was :@0.076185:0.098728:0.485130:0.098723:0.485130:0.082941:0.076185:0.082945:0.010326:0.004747:0.005125:0.009827:0.004551:0.005518:0.009223:0.010326:0.008376:0.003024:0.009223:0.010175:0.005534:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.009782:0.009827:0.010357:0.005518:0.006441:0.008678:0.005518:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.009712:0.005518:0.006441:0.009223:0.009827:0.005518:0.010326:0.003024:0.014182:0.005534:0.012564:0.010326:0.005866:0.719969
14:@0.372873:0.093425:0.382589:0.093425:0.382589:0.084271:0.372873:0.084271:0.004858:0.004858
to evaluate prednisone for the prevention (rather than :@0.076190:0.112520:0.485160:0.112520:0.485160:0.096738:0.076190:0.096738:0.005125:0.009903:0.005110:0.009827:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.009827:0.005110:0.010311:0.004551:0.009827:0.010357:0.009223:0.003024:0.005866:0.009903:0.009223:0.009827:0.005110:0.004747:0.009903:0.004551:0.005110:0.005125:0.009223:0.009827:0.005110:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.005110:0.005579:0.004551:0.010326:0.005125:0.009223:0.009827:0.004551:0.005110:0.005125:0.009223:0.010326:0.009223:0.004188
treatment)  of TB IRIs. Those  in the  treatment  arm re-:@0.076190:0.126317:0.480957:0.126317:0.480957:0.110534:0.076190:0.110534:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.005579:0.004188:0.003462:0.009903:0.004747:0.007665:0.006441:0.008678:0.007665:0.003417:0.009177:0.003417:0.007529:0.004188:0.007665:0.006441:0.009223:0.009903:0.005866:0.009827:0.004188:0.003462:0.003024:0.009223:0.007665:0.005125:0.009223:0.009827:0.004188:0.003462:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.003462:0.010326:0.004551:0.014182:0.007665:0.004551:0.009827:0.005020
ceived 40 mg prednisone per day for two weeks, fol-:@0.076190:0.140114:0.480942:0.140114:0.480942:0.124331:0.076190:0.124331:0.009782:0.009827:0.003024:0.008376:0.009827:0.010357:0.006395:0.008376:0.008376:0.006395:0.014182:0.010175:0.006395:0.010311:0.004551:0.009827:0.010357:0.009223:0.003024:0.005866:0.009903:0.009223:0.009827:0.006380:0.010311:0.009827:0.004551:0.006395:0.010357:0.010326:0.008104:0.006395:0.004747:0.009903:0.004551:0.006380:0.005125:0.012564:0.009903:0.006380:0.012564:0.009827:0.009827:0.007590:0.005866:0.004188:0.006395:0.004747:0.009903:0.003024:0.005020
lowed by 20 mg per day for two weeks (see Table 4). :@0.076190:0.153911:0.485130:0.153911:0.485130:0.138128:0.076190:0.138128:0.003024:0.009903:0.012564:0.009827:0.010357:0.005851:0.010311:0.008104:0.005866:0.008376:0.008376:0.005866:0.014182:0.010175:0.005851:0.010311:0.009827:0.004551:0.005851:0.010357:0.010326:0.008104:0.005866:0.004747:0.009903:0.004551:0.005851:0.005125:0.012564:0.009903:0.005851:0.012564:0.009827:0.009827:0.007590:0.005866:0.005851:0.005579:0.005866:0.009827:0.009827:0.005866:0.006441:0.010326:0.010311:0.003024:0.009827:0.005866:0.008376:0.005579:0.004188:0.004188
Forty-seven percent of the placebo group developed :@0.076190:0.167707:0.485130:0.167707:0.485130:0.151925:0.076190:0.151925:0.007333:0.009903:0.004551:0.005125:0.008104:0.005020:0.005866:0.009827:0.008376:0.009827:0.009223:0.005775:0.010311:0.009827:0.004551:0.009782:0.009827:0.009223:0.005125:0.005775:0.009903:0.004747:0.005791:0.005125:0.009223:0.009827:0.005791:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.005791:0.010175:0.004551:0.009903:0.009192:0.010311:0.005775:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.009827:0.010357:0.004188
TB IRIs, compared with 33% of the prednisone group. This :@0.076190:0.181504:0.485145:0.181504:0.485145:0.165722:0.076190:0.165722:0.006441:0.008678:0.003387:0.003417:0.009177:0.003417:0.007529:0.004188:0.003387:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.003387:0.012564:0.003024:0.005125:0.009223:0.003387:0.008376:0.008376:0.011717:0.003387:0.009903:0.004747:0.003387:0.005125:0.009223:0.009827:0.003387:0.010311:0.004551:0.009827:0.010357:0.009223:0.003024:0.005866:0.009903:0.009223:0.009827:0.003387:0.010175:0.004551:0.009903:0.009192:0.010311:0.004188:0.003372:0.006441:0.009223:0.003024:0.005866:0.004188
translates into a 30% relative risk reduction for the pred-:@0.076190:0.195301:0.480957:0.195301:0.480957:0.179518:0.076190:0.179518:0.005125:0.004551:0.010326:0.009223:0.005866:0.003024:0.010326:0.005125:0.009827:0.005866:0.004430:0.003024:0.009223:0.005125:0.009903:0.004430:0.010326:0.004430:0.008376:0.008376:0.011717:0.004445:0.004551:0.009827:0.003024:0.010326:0.005125:0.003024:0.008376:0.009827:0.004430:0.004551:0.003024:0.005866:0.007590:0.004445:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004430:0.004747:0.009903:0.004551:0.004430:0.005125:0.009223:0.009827:0.004430:0.010311:0.004551:0.009827:0.010357:0.005020
nisone group or the prevention of one case of TB IRIs :@0.076190:0.209098:0.485130:0.209098:0.485130:0.193315:0.076190:0.193315:0.009223:0.003024:0.005866:0.009903:0.009223:0.009827:0.006290:0.010175:0.004551:0.009903:0.009192:0.010311:0.006274:0.009903:0.004551:0.006274:0.005125:0.009223:0.009827:0.006274:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.003024:0.009903:0.009223:0.006274:0.009903:0.004747:0.006290:0.009903:0.009223:0.009827:0.006274:0.009782:0.010326:0.005866:0.009827:0.006290:0.009903:0.004747:0.006290:0.006441:0.008678:0.006290:0.003417:0.009177:0.003417:0.007529:0.004188
for every seven patients treated with prednisone. Again, :@0.076190:0.222895:0.485160:0.222895:0.485160:0.207112:0.076190:0.207112:0.004747:0.009903:0.004551:0.003341:0.009827:0.008376:0.009827:0.004551:0.008104:0.003356:0.005866:0.009827:0.008376:0.009827:0.009223:0.003356:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003356:0.005125:0.004551:0.009827:0.010326:0.005125:0.009812:0.010357:0.003356:0.012564:0.003024:0.005125:0.009223:0.003356:0.010311:0.004551:0.009827:0.010357:0.009223:0.003024:0.005866:0.009903:0.009223:0.009827:0.004188:0.003341:0.011188:0.010175:0.010326:0.003024:0.009223:0.004188:0.004188
despite this, no effect on mortality was seen. There was :@0.076190:0.236691:0.485145:0.236691:0.485145:0.220909:0.076190:0.220909:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.004566:0.005125:0.009223:0.003024:0.005866:0.004188:0.004551:0.009223:0.009903:0.004566:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004551:0.009903:0.009223:0.004551:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.004566:0.012564:0.010326:0.005866:0.004566:0.005866:0.009827:0.009827:0.009223:0.004188:0.004551:0.006441:0.009223:0.009827:0.004551:0.009827:0.004551:0.012564:0.010326:0.005866:0.004188
no significant difference in rates of serious infection or :@0.076190:0.250488:0.485115:0.250488:0.485115:0.234706:0.076190:0.234706:0.009223:0.009903:0.005927:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.005927:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005927:0.003024:0.009223:0.005927:0.004551:0.010326:0.005125:0.009827:0.005866:0.005927:0.009903:0.004747:0.005927:0.005866:0.009827:0.004551:0.003024:0.009903:0.009192:0.005866:0.005927:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.005927:0.009903:0.004551:0.004188
neoplasm between  the  two  groups.  It must be noted :@0.076190:0.264285:0.485130:0.264285:0.485130:0.248502:0.076190:0.248502:0.009223:0.009827:0.009903:0.010311:0.003024:0.010326:0.005866:0.014182:0.006501:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.004188:0.002298:0.005125:0.009223:0.009827:0.004188:0.002298:0.005125:0.012564:0.009903:0.004188:0.002298:0.010175:0.004551:0.009903:0.009192:0.010311:0.005866:0.004188:0.004188:0.002298:0.003417:0.005125:0.006501:0.014182:0.009192:0.005866:0.005125:0.006501:0.010311:0.009827:0.006501:0.009223:0.009903:0.005125:0.009827:0.010357:0.004188
that important subgroups of patients were excluded in :@0.076190:0.278082:0.485130:0.278082:0.485130:0.262299:0.076190:0.262299:0.005125:0.009223:0.010326:0.005125:0.005095:0.003024:0.014182:0.010311:0.009903:0.004551:0.005125:0.010326:0.009223:0.005125:0.005095:0.005866:0.009192:0.010311:0.010175:0.004551:0.009903:0.009192:0.010311:0.005866:0.005095:0.009903:0.004747:0.005095:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005110:0.012564:0.009827:0.004551:0.009827:0.005095:0.009827:0.007257:0.009782:0.003024:0.009192:0.010357:0.009827:0.010357:0.005110:0.003024:0.009223:0.004188
this trial – amongst others, patients with hepatitis B co-:@0.076190:0.291879:0.480972:0.291879:0.480972:0.276096:0.076190:0.276096:0.005125:0.009223:0.003024:0.005866:0.005609:0.005125:0.004551:0.003024:0.010326:0.003024:0.005609:0.007560:0.005609:0.010326:0.014182:0.009903:0.009223:0.010175:0.005866:0.005125:0.005594:0.009903:0.005125:0.009223:0.009827:0.004551:0.005866:0.004188:0.005594:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005609:0.012564:0.003024:0.005125:0.009223:0.005609:0.009223:0.009827:0.010311:0.010326:0.005125:0.003024:0.005125:0.003024:0.005866:0.005609:0.008678:0.005609:0.009782:0.009903:0.005020
infection,  those with pericardial or rifampicin-resistant :@0.076190:0.305675:0.485130:0.305675:0.485130:0.289893:0.076190:0.289893:0.003024:0.009223:0.004747:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.003220:0.005125:0.009223:0.009903:0.005866:0.009827:0.007423:0.012564:0.003024:0.005125:0.009223:0.007423:0.010311:0.009827:0.004551:0.003024:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.003024:0.007423:0.009903:0.004551:0.007423:0.004551:0.003024:0.004747:0.010326:0.014182:0.010311:0.003024:0.009782:0.003024:0.009223:0.005020:0.004551:0.009827:0.005866:0.003024:0.005866:0.005125:0.010326:0.009223:0.005125:0.004188
TB, those on non-standard TB regimens, those with Ka-:@0.076190:0.319472:0.480942:0.319472:0.480942:0.303690:0.076190:0.303690:0.006441:0.008678:0.004188:0.005851:0.005125:0.009223:0.009903:0.005866:0.009827:0.005836:0.009903:0.009223:0.005836:0.009223:0.009903:0.009223:0.005020:0.005866:0.005125:0.010326:0.009223:0.010357:0.010326:0.004551:0.010357:0.005836:0.006441:0.008678:0.005851:0.004551:0.009827:0.010175:0.003024:0.014182:0.009827:0.009223:0.005866:0.004188:0.005836:0.005125:0.009223:0.009903:0.005866:0.009827:0.005836:0.012564:0.003024:0.005125:0.009223:0.005851:0.008935:0.010326:0.005020
posi sarcoma and those  with uncontrolled  diabetes. :@0.076190:0.333269:0.485145:0.333269:0.485145:0.317486:0.076190:0.317486:0.010311:0.009903:0.005866:0.003024:0.008164:0.005866:0.010326:0.004551:0.009782:0.009903:0.014182:0.010326:0.008164:0.010326:0.009223:0.010357:0.008164:0.005125:0.009223:0.009903:0.005866:0.009827:0.004188:0.003961:0.012564:0.003024:0.005125:0.009223:0.008164:0.009192:0.009223:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.003024:0.009827:0.010357:0.004188:0.003961:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004188
Also, only adults were enrolled. Thus, the extrapolation :@0.076190:0.347066:0.485145:0.347066:0.485145:0.331283:0.076190:0.331283:0.011188:0.003024:0.005866:0.009903:0.004188:0.005534:0.009903:0.009223:0.003024:0.008104:0.005534:0.010326:0.010357:0.009192:0.003024:0.005125:0.005866:0.005549:0.012564:0.009827:0.004551:0.009827:0.005534:0.009827:0.009223:0.004551:0.009903:0.003024:0.003024:0.009827:0.010357:0.004188:0.005534:0.006441:0.009223:0.009192:0.005866:0.004188:0.005534:0.005125:0.009223:0.009827:0.005534:0.009827:0.007257:0.005125:0.004551:0.010326:0.010311:0.009903:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
of these generalised results to routine clinical practice :@0.076190:0.360863:0.485145:0.360863:0.485145:0.345080:0.076190:0.345080:0.009903:0.004747:0.005851:0.005125:0.009223:0.009827:0.005866:0.009827:0.005851:0.010175:0.009827:0.009223:0.009827:0.004551:0.010326:0.003024:0.003024:0.005866:0.009827:0.010357:0.005851:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.005851:0.005125:0.009903:0.005851:0.004551:0.009903:0.009192:0.005125:0.003024:0.009223:0.009827:0.005836:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.005866:0.010311:0.004551:0.010326:0.009782:0.005125:0.003024:0.009782:0.009827:0.004188
may be somewhat limited. Nonetheless, the trial does :@0.076190:0.374660:0.485130:0.374660:0.485130:0.358877:0.076190:0.358877:0.014182:0.010326:0.008104:0.006138:0.010311:0.009827:0.006138:0.005866:0.009903:0.014182:0.009827:0.012564:0.009223:0.010326:0.005125:0.006138:0.003024:0.003024:0.014182:0.003024:0.005125:0.009827:0.010357:0.004188:0.006138:0.011188:0.009903:0.009223:0.009827:0.005125:0.009223:0.009827:0.003024:0.009827:0.005866:0.005866:0.004188:0.006138:0.005125:0.009223:0.009827:0.006138:0.005125:0.004551:0.003024:0.010326:0.003024:0.006138:0.010357:0.009903:0.009827:0.005866:0.004188
suggest that prednisone may safely  prevent TB IRIs in :@0.076190:0.388456:0.485130:0.388456:0.485130:0.372674:0.076190:0.372674:0.005866:0.009192:0.010175:0.010175:0.009827:0.005866:0.005125:0.006743:0.005125:0.009223:0.010326:0.005125:0.006743:0.010311:0.004551:0.009827:0.010357:0.009223:0.003024:0.005866:0.009903:0.009223:0.009827:0.006743:0.014182:0.010326:0.008104:0.006743:0.005866:0.010326:0.004747:0.009827:0.003024:0.008104:0.004188:0.002570:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.006743:0.006441:0.008678:0.006743:0.003417:0.009177:0.003417:0.007529:0.006743:0.003024:0.009223:0.004188
many HIV patients commencing ART, provided the pa-:@0.076190:0.402253:0.480927:0.402253:0.480927:0.386471:0.076190:0.386471:0.014182:0.010326:0.009223:0.008104:0.004702:0.010326:0.003417:0.010614:0.004702:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004702:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.009782:0.003024:0.009223:0.010175:0.004687:0.011188:0.009177:0.006441:0.004188:0.004687:0.010311:0.004551:0.009903:0.008376:0.003024:0.010357:0.009827:0.010357:0.004702:0.005125:0.009223:0.009827:0.004702:0.010311:0.010326:0.005020
tient has been carefully evaluated for any contra-indi-:@0.076190:0.416050:0.480957:0.416050:0.480957:0.400267:0.076190:0.400267:0.005125:0.003024:0.009827:0.009223:0.005125:0.005352:0.009223:0.010326:0.005866:0.005352:0.010311:0.009827:0.009827:0.009223:0.005352:0.009782:0.010326:0.004551:0.009827:0.004747:0.009192:0.003024:0.003024:0.008104:0.005352:0.009827:0.008376:0.010326:0.003024:0.009192:0.010326:0.005125:0.009827:0.010357:0.005352:0.004747:0.009903:0.004551:0.005337:0.010326:0.009223:0.008104:0.005352:0.009782:0.009903:0.009223:0.005125:0.004551:0.010326:0.005020:0.003024:0.009223:0.010357:0.003024:0.005020
cating conditions beforehand. :@0.076190:0.429847:0.304321:0.429847:0.304321:0.414064:0.076190:0.414064:0.009782:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188:0.009782:0.009903:0.009223:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.010311:0.009827:0.004747:0.009903:0.004551:0.009827:0.009223:0.010326:0.009223:0.010357:0.004188:0.004188
table 4. suggested prednisone regimen for the :@0.077030:0.462830:0.421744:0.462830:0.421744:0.446332:0.077030:0.446332:0.006350:0.009979:0.009979:0.003629:0.009676:0.004233:0.008467:0.004233:0.004233:0.007862:0.009071:0.009979:0.009979:0.009676:0.006652:0.004536:0.009676:0.009979:0.004233:0.009979:0.004838:0.009676:0.009979:0.009071:0.003629:0.006652:0.009676:0.009071:0.009676:0.004233:0.004838:0.009676:0.009979:0.003629:0.014212:0.009676:0.009071:0.004233:0.004233:0.009676:0.004838:0.004233:0.004536:0.009071:0.009676:0.004233
prophylaxis of paradoxical tb iris in adults:@0.077030:0.476939:0.387575:0.476939:0.387575:0.460440:0.077030:0.460440:0.009979:0.004838:0.009676:0.009979:0.009071:0.008769:0.003629:0.009979:0.008467:0.003629:0.006652:0.004233:0.009676:0.004233:0.004233:0.009979:0.009979:0.004838:0.009979:0.009979:0.009676:0.008467:0.003629:0.009676:0.009979:0.003629:0.004233:0.006350:0.008769:0.004233:0.004233:0.008769:0.004233:0.007862:0.004233:0.003629:0.009071:0.004233:0.009979:0.009979:0.009071:0.003629:0.004536:0.006652
prednisone 40 mg/day for two weeks, followed by:@0.082070:0.495790:0.406504:0.495790:0.406504:0.481761:0.082070:0.481761:0.007956:0.004045:0.008735:0.009206:0.008198:0.002688:0.005214:0.008803:0.008198:0.008735:0.003723:0.007445:0.007445:0.003723:0.012606:0.009045:0.005873:0.009206:0.009179:0.007203:0.003723:0.004220:0.008803:0.004045:0.003723:0.004556:0.011168:0.008803:0.003723:0.011168:0.008735:0.008735:0.006746:0.005214:0.003723:0.003723:0.004220:0.008803:0.002688:0.002688:0.008803:0.011168:0.008735:0.009206:0.003723:0.009165:0.007203
prednisone 20 mg/day for two weeks:@0.082070:0.511184:0.322658:0.511184:0.322658:0.497155:0.082070:0.497155:0.007956:0.004045:0.008735:0.009206:0.008198:0.002688:0.005214:0.008803:0.008198:0.008735:0.003723:0.007445:0.007445:0.003723:0.012606:0.009045:0.005873:0.009206:0.009179:0.007203:0.003723:0.004220:0.008803:0.004045:0.003723:0.004556:0.011168:0.008803:0.003723:0.011168:0.008735:0.008735:0.006746:0.005214
referenCes:@0.076190:0.551172:0.182628:0.551172:0.182628:0.531008:0.076190:0.531008:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.076190:0.562748:0.089220:0.562748:0.089220:0.550472:0.076190:0.550472:0.006515:0.003257:0.003257
World Health Organization. Global Tuberculosis Report 2018. Avail-:@0.101390:0.562748:0.480944:0.562748:0.480944:0.550472:0.101390:0.550472:0.011289:0.007702:0.003540:0.002352:0.008055:0.003869:0.008032:0.007644:0.008032:0.002352:0.003986:0.007173:0.003869:0.010219:0.003540:0.007914:0.008032:0.007173:0.002352:0.004998:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003869:0.010254:0.002352:0.007702:0.008020:0.008032:0.002352:0.003881:0.005009:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003869:0.007138:0.007644:0.008020:0.007702:0.003540:0.003986:0.003869:0.006515:0.006515:0.006515:0.006515:0.003257:0.003881:0.008702:0.006515:0.008032:0.002352:0.002352:0.003904
able  at:  https://www.who.int/tb/publications/global_report/en/ :@0.101390:0.573335:0.484225:0.573335:0.484225:0.561059:0.101390:0.561059:0.008032:0.008020:0.002352:0.007644:0.003257:0.008996:0.008032:0.003986:0.003257:0.003257:0.008984:0.007173:0.003986:0.003986:0.008020:0.004563:0.003257:0.005139:0.005139:0.009772:0.009772:0.009772:0.003257:0.009772:0.007173:0.007702:0.003257:0.002352:0.007173:0.003986:0.005139:0.003986:0.008020:0.005139:0.008020:0.007150:0.008020:0.002352:0.002352:0.007608:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.005139:0.007914:0.002352:0.007702:0.008020:0.008032:0.002352:0.005880:0.003540:0.007644:0.008020:0.007702:0.003540:0.003986:0.005139:0.007644:0.007173:0.005139:0.003257
Accessed January 2019.:@0.101390:0.583922:0.239503:0.583922:0.239503:0.571647:0.101390:0.571647:0.008702:0.007608:0.007608:0.007644:0.004563:0.004563:0.007644:0.008055:0.003257:0.005668:0.008032:0.007173:0.007150:0.008032:0.003540:0.006303:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
2. :@0.076190:0.594509:0.089220:0.594509:0.089220:0.582234:0.076190:0.582234:0.006515:0.003257:0.003257
Müller  M, :@0.101390:0.594509:0.157847:0.594509:0.157847:0.582234:0.101390:0.582234:0.010807:0.007150:0.002352:0.002352:0.007644:0.003540:0.003257:0.002034:0.010807:0.003257:0.003257
et  al:@0.159893:0.594509:0.187198:0.594509:0.187198:0.582234:0.159893:0.582234:0.007644:0.003986:0.003257:0.002034:0.008032:0.002352
.  Immune  reconstitution  inflammatory  syndrome  in :@0.187198:0.594509:0.484201:0.594509:0.484201:0.582234:0.187198:0.582234:0.003257:0.003257:0.002034:0.002658:0.011030:0.011030:0.007150:0.007173:0.007644:0.003257:0.002034:0.003540:0.007644:0.007608:0.007702:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.003257:0.002034:0.002352:0.007173:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.003257:0.002046:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.002034:0.002352:0.007173:0.003257
patients starting antiretroviral therapy for HIV infection: A systematic :@0.101390:0.605096:0.484201:0.605096:0.484201:0.592821:0.101390:0.592821:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.002658:0.004563:0.003986:0.008032:0.003540:0.003986:0.002352:0.007173:0.007914:0.002658:0.008032:0.007173:0.003986:0.002352:0.003540:0.007644:0.003986:0.003540:0.007702:0.006515:0.002352:0.003540:0.008032:0.002352:0.002646:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.002658:0.003692:0.007702:0.003540:0.002646:0.008032:0.002658:0.008255:0.002658:0.002352:0.007173:0.003692:0.007644:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.002646:0.008702:0.002658:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.003257
review and meta-analysis. :@0.101390:0.615683:0.253108:0.615683:0.253108:0.603408:0.101390:0.603408:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.008032:0.007173:0.008055:0.003257:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003257
Lancet Infect Dis:@0.253108:0.615683:0.347923:0.615683:0.347923:0.603408:0.253108:0.603408:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257:0.002658:0.007173:0.003692:0.007644:0.007608:0.003986:0.003257:0.008749:0.002352:0.004563
. 2010;10:251-61:@0.347923:0.615683:0.436517:0.615683:0.436517:0.603408:0.347923:0.603408:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515
3. :@0.076190:0.626271:0.089220:0.626271:0.089220:0.613995:0.076190:0.613995:0.006515:0.003257:0.003257
Burman W, :@0.101390:0.626271:0.167407:0.626271:0.167407:0.613995:0.101390:0.613995:0.006750:0.007150:0.003540:0.011030:0.008032:0.007173:0.004539:0.011289:0.003257:0.003257
et al:@0.168689:0.626271:0.195241:0.626271:0.195241:0.613995:0.168689:0.613995:0.007644:0.003986:0.004539:0.008032:0.002352
. Frequency, severity and duration of immune re-:@0.195241:0.626271:0.480956:0.626271:0.480956:0.613995:0.195241:0.613995:0.003257:0.004539:0.005703:0.003540:0.007644:0.008020:0.007150:0.007644:0.007173:0.007608:0.006303:0.003257:0.004527:0.004563:0.007644:0.006515:0.007644:0.003540:0.002352:0.003986:0.006303:0.004539:0.008032:0.007173:0.008055:0.004539:0.008055:0.007150:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.004539:0.007702:0.003692:0.004539:0.002352:0.011030:0.011030:0.007150:0.007173:0.007644:0.004539:0.003540:0.007644:0.003904
constitution events in HIV-related tuberculosis. :@0.101390:0.636858:0.363739:0.636858:0.363739:0.624582:0.101390:0.624582:0.007608:0.007702:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.003081:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.003081:0.002352:0.007173:0.003081:0.008032:0.002658:0.008255:0.003904:0.003540:0.007644:0.002352:0.008032:0.003986:0.007644:0.008055:0.003081:0.003986:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003257:0.003257
Int J Tuberc Lung Dis:@0.363575:0.636858:0.477686:0.636858:0.477686:0.624582:0.363575:0.624582:0.002658:0.007173:0.003986:0.003081:0.005668:0.003081:0.005009:0.007150:0.008020:0.007644:0.003540:0.007608:0.003081:0.005433:0.007150:0.007173:0.007914:0.003081:0.008749:0.002352:0.004563
. :@0.477686:0.636858:0.484201:0.636858:0.484201:0.624582:0.477686:0.624582:0.003257:0.003257
2007;11(12):1282-9:@0.101390:0.647445:0.205178:0.647445:0.205178:0.635170:0.101390:0.635170:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515
4. :@0.076190:0.658032:0.089220:0.658032:0.089220:0.645757:0.076190:0.645757:0.006515:0.003257:0.003257
Meintjes G, :@0.101390:0.658032:0.170699:0.658032:0.170699:0.645757:0.101390:0.645757:0.010807:0.007644:0.002352:0.007173:0.003986:0.002387:0.007644:0.004563:0.005985:0.010254:0.003257:0.003257
et  al:@0.173416:0.658032:0.201403:0.658032:0.201403:0.645757:0.173416:0.645757:0.007644:0.003986:0.003257:0.002716:0.008032:0.002352
.  Randomized  placebo-controlled  trial of  pred-:@0.201403:0.658032:0.480932:0.658032:0.480932:0.645757:0.201403:0.645757:0.003257:0.003257:0.002716:0.007138:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.003257:0.002716:0.008020:0.002352:0.008032:0.007608:0.007644:0.008020:0.007702:0.003904:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.003257:0.002716:0.003986:0.003540:0.002352:0.008032:0.002352:0.005985:0.007702:0.003692:0.003257:0.002716:0.008020:0.003540:0.007644:0.008055:0.003904
nisone for paradoxical tuberculosis-associated immune reconstitu-:@0.101390:0.668619:0.480956:0.668619:0.480956:0.656344:0.101390:0.656344:0.007173:0.002352:0.004563:0.007702:0.007173:0.007644:0.003916:0.003692:0.007702:0.003540:0.003916:0.008020:0.008032:0.003540:0.008032:0.008055:0.007702:0.005644:0.002352:0.007608:0.008032:0.002352:0.003928:0.003986:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003904:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.003928:0.002352:0.011030:0.011030:0.007150:0.007173:0.007644:0.003916:0.003540:0.007644:0.007608:0.007702:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003904
tion inflammatory syndrome. :@0.101390:0.679207:0.266526:0.679207:0.266526:0.666931:0.101390:0.666931:0.003986:0.002352:0.007702:0.007173:0.003257:0.002352:0.007173:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.003257:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.003257
AIDS.:@0.266502:0.679207:0.295724:0.679207:0.295724:0.666931:0.266502:0.666931:0.008702:0.002658:0.008749:0.005856:0.003257
 2010;24:2381-2390:@0.295724:0.679207:0.400605:0.679207:0.400605:0.666931:0.295724:0.666931:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515
5. :@0.076190:0.689794:0.089220:0.689794:0.089220:0.677518:0.076190:0.677518:0.006515:0.003257:0.003257
Agarwal U, :@0.101390:0.689794:0.167407:0.689794:0.167407:0.677518:0.101390:0.677518:0.008702:0.007914:0.008032:0.003540:0.009772:0.008032:0.002352:0.003457:0.007702:0.003257:0.003257
et al.:@0.167595:0.689794:0.196323:0.689794:0.196323:0.677518:0.167595:0.677518:0.007644:0.003986:0.003457:0.008032:0.002352:0.003257
 Tuberculosis-associated immune reconstitution in-:@0.196323:0.689794:0.480944:0.689794:0.480944:0.677518:0.196323:0.677518:0.003457:0.005009:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003904:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.003457:0.002352:0.011030:0.011030:0.007150:0.007173:0.007644:0.003457:0.003540:0.007644:0.007608:0.007691:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.003445:0.002352:0.007173:0.003904
flammatory syndrome in patients infected with HIV: Meningitis a po:@0.101390:0.700381:0.477040:0.700381:0.477040:0.688105:0.101390:0.688105:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.002810:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.002810:0.002352:0.007173:0.002810:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.002810:0.002352:0.007173:0.003692:0.007644:0.007608:0.003986:0.007644:0.008055:0.002810:0.009772:0.002352:0.003986:0.007173:0.002810:0.008032:0.002658:0.008255:0.003257:0.002810:0.010807:0.007644:0.007173:0.002352:0.007173:0.007914:0.002352:0.003986:0.002352:0.004563:0.002810:0.008032:0.002810:0.008020:0.007702
-:@0.477040:0.700381:0.480944:0.700381:0.480944:0.688105:0.477040:0.688105:0.003904
tentially life-threatening manifestation. :@0.101390:0.710968:0.321806:0.710968:0.321806:0.698693:0.101390:0.698693:0.003986:0.007644:0.007173:0.003986:0.002352:0.008032:0.002352:0.002352:0.006303:0.002728:0.002352:0.002352:0.003692:0.007644:0.003904:0.003986:0.007173:0.003540:0.007644:0.008032:0.003986:0.007644:0.007173:0.002352:0.007173:0.007914:0.002716:0.011030:0.008032:0.007173:0.002352:0.003692:0.007644:0.004563:0.003986:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
AIDS Research and Therapy:@0.321265:0.710968:0.477698:0.710968:0.477698:0.698693:0.321265:0.698693:0.008702:0.002658:0.008749:0.005856:0.002716:0.007138:0.007644:0.004563:0.007644:0.008032:0.003540:0.007608:0.007173:0.002716:0.008032:0.007173:0.008055:0.002716:0.005009:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303
. :@0.477698:0.710968:0.484213:0.710968:0.484213:0.698693:0.477698:0.698693:0.003257:0.003257
2012;9(17):@0.101390:0.721555:0.158928:0.721555:0.158928:0.709280:0.101390:0.709280:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.004339:0.006515:0.006515:0.004339
6. :@0.076190:0.732142:0.089220:0.732142:0.089220:0.719867:0.076190:0.719867:0.006515:0.003257:0.003257
Geri G, :@0.101390:0.732142:0.144712:0.732142:0.144712:0.719867:0.101390:0.719867:0.010254:0.007644:0.003540:0.002352:0.002763:0.010254:0.003257:0.003257
et al.:@0.144218:0.732142:0.172252:0.732142:0.172252:0.719867:0.144218:0.719867:0.007644:0.003986:0.002763:0.008032:0.002352:0.003257
 paradoxical reactions during treatment of tuberculosis :@0.172252:0.732142:0.484213:0.732142:0.484213:0.719867:0.172252:0.719867:0.002763:0.006961:0.008032:0.003540:0.008032:0.008055:0.007702:0.005644:0.002352:0.007608:0.008032:0.002352:0.002763:0.003540:0.007644:0.008032:0.007608:0.003986:0.002352:0.007702:0.007173:0.004563:0.002763:0.008055:0.007150:0.003540:0.002352:0.007173:0.007914:0.002763:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.002752:0.007702:0.003692:0.002763:0.003986:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003257
with extrapulmonary manifestations in HIV-negative patients. :@0.101390:0.742730:0.448465:0.742730:0.448465:0.730454:0.101390:0.730454:0.009772:0.002352:0.003986:0.007173:0.003093:0.007644:0.005644:0.003986:0.003540:0.008032:0.008020:0.007150:0.002352:0.011030:0.007702:0.007173:0.008032:0.003540:0.006303:0.003093:0.011030:0.008032:0.007173:0.002352:0.003692:0.007644:0.004563:0.003986:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.003093:0.002352:0.007173:0.003093:0.008032:0.002658:0.008255:0.003904:0.007173:0.007644:0.007914:0.008032:0.003986:0.002352:0.006515:0.007644:0.003093:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.003257
Infec-:@0.448300:0.742730:0.480979:0.742730:0.480979:0.730454:0.448300:0.730454:0.002658:0.007173:0.003692:0.007644:0.007608:0.003904
tion:@0.101390:0.753317:0.122604:0.753317:0.122604:0.741041:0.101390:0.741041:0.003986:0.002352:0.007702:0.007173
. 2013; 41:537-543:@0.122604:0.753317:0.220970:0.753317:0.220970:0.741041:0.122604:0.741041:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515
7. :@0.076190:0.763904:0.088984:0.763904:0.088984:0.751629:0.076190:0.751629:0.006397:0.003140:0.003257
Grant pM, :@0.101390:0.763904:0.162080:0.763904:0.162080:0.751629:0.101390:0.751629:0.010136:0.003422:0.007914:0.007056:0.003869:0.004363:0.006844:0.010689:0.003140:0.003257
et al.:@0.163185:0.763904:0.192348:0.763904:0.192348:0.751629:0.163185:0.751629:0.007526:0.003869:0.004363:0.007914:0.002234:0.003257
 Risk factor analyses for immune reconstitution syn-:@0.192231:0.763904:0.480944:0.763904:0.480944:0.751629:0.192231:0.751629:0.004363:0.007020:0.002234:0.004445:0.005786:0.004363:0.003575:0.007914:0.007491:0.003869:0.007585:0.003422:0.004363:0.007914:0.007056:0.007914:0.002234:0.006185:0.004445:0.007526:0.004445:0.004363:0.003575:0.007585:0.003422:0.004363:0.002234:0.010913:0.010913:0.007032:0.007056:0.007526:0.004363:0.003422:0.007526:0.007491:0.007585:0.007056:0.004445:0.003869:0.002234:0.003869:0.007032:0.003869:0.002234:0.007585:0.007056:0.004363:0.004445:0.006185:0.007056:0.003904
drome  in  a  randomized  study  of  early  vs  deferred  ART  during  an :@0.101390:0.774491:0.484178:0.774491:0.484178:0.762216:0.101390:0.762216:0.007937:0.003422:0.007585:0.010913:0.007526:0.003257:0.002093:0.002234:0.007056:0.003257:0.002093:0.007914:0.003257:0.002093:0.003422:0.007914:0.007056:0.007937:0.007585:0.010913:0.002234:0.004880:0.007526:0.007937:0.003257:0.002093:0.004445:0.003869:0.007032:0.007937:0.006185:0.003257:0.002093:0.007585:0.003575:0.003257:0.002093:0.007526:0.007914:0.003422:0.002234:0.006185:0.003257:0.002093:0.006397:0.004445:0.003257:0.002093:0.007937:0.007526:0.003575:0.007526:0.003422:0.003422:0.007526:0.007937:0.003257:0.002093:0.008584:0.007020:0.004892:0.003257:0.002093:0.007937:0.007032:0.003422:0.002234:0.007056:0.007796:0.003257:0.002093:0.007914:0.007173:0.003257
opportunistic infection. pLos One. 2010;5(7):e11416. Epub 2010 Jul 1.:@0.101390:0.785078:0.479039:0.785078:0.479039:0.772803:0.101390:0.772803:0.007585:0.007902:0.007902:0.007585:0.003422:0.003869:0.007032:0.007056:0.002234:0.004445:0.003869:0.002234:0.007491:0.003140:0.002234:0.007056:0.003575:0.007526:0.007491:0.003869:0.002234:0.007585:0.007056:0.003140:0.003140:0.006844:0.005315:0.007585:0.005739:0.003140:0.010101:0.007056:0.007526:0.003140:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.006397:0.004222:0.006397:0.004222:0.003140:0.007526:0.006397:0.006397:0.006397:0.006397:0.006397:0.003140:0.003140:0.006185:0.007902:0.007032:0.007902:0.003140:0.006397:0.006397:0.006397:0.006397:0.003140:0.005550:0.007032:0.002234:0.003140:0.006397:0.003257
8. :@0.076190:0.795665:0.089220:0.795665:0.089220:0.783390:0.076190:0.783390:0.006515:0.003257:0.003257
French MA, :@0.101390:0.795665:0.169135:0.795665:0.169135:0.783390:0.101390:0.783390:0.005703:0.003540:0.007644:0.007173:0.007608:0.007173:0.002881:0.010807:0.008702:0.003257:0.003257
et al.:@0.168759:0.795665:0.196911:0.795665:0.196911:0.783390:0.168759:0.783390:0.007644:0.003986:0.002881:0.008032:0.002352:0.003257
 Immune restoration disease after the treatment of :@0.196911:0.795665:0.484213:0.795665:0.484213:0.783390:0.196911:0.783390:0.002881:0.002658:0.011030:0.011030:0.007150:0.007173:0.007644:0.002881:0.003540:0.007644:0.004563:0.003986:0.007702:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.002881:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.002893:0.008032:0.003692:0.003986:0.007644:0.003540:0.002881:0.003986:0.007173:0.007644:0.002881:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.002881:0.007702:0.003692:0.003257
immunodeficient HIV-infected patients with highly active antiretro:@0.101390:0.806253:0.477063:0.806253:0.477063:0.793977:0.101390:0.793977:0.002352:0.011030:0.011030:0.007150:0.007173:0.007702:0.008055:0.007644:0.002863:0.002863:0.007608:0.002352:0.007644:0.007173:0.003986:0.003598:0.008032:0.002658:0.008255:0.003904:0.002352:0.007173:0.003692:0.007644:0.007608:0.003986:0.007644:0.008055:0.003610:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003610:0.009772:0.002352:0.003986:0.007173:0.003610:0.007173:0.002352:0.007914:0.007173:0.002352:0.006303:0.003610:0.008032:0.007608:0.003986:0.002352:0.006515:0.007644:0.003610:0.008032:0.007173:0.003986:0.002352:0.003540:0.007644:0.003986:0.003540:0.007702
-:@0.477051:0.806253:0.480956:0.806253:0.480956:0.793977:0.477051:0.793977:0.003904
viral therapy. :@0.101390:0.816840:0.178649:0.816840:0.178649:0.804564:0.101390:0.804564:0.006515:0.002352:0.003540:0.008032:0.002352:0.003257:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.003257:0.003257
HIV Med:@0.178649:0.816840:0.227356:0.816840:0.227356:0.804564:0.178649:0.804564:0.008032:0.002658:0.008255:0.003257:0.010807:0.007644:0.008055
. 2000; 1(2):107:@0.227356:0.816840:0.310952:0.816840:0.310952:0.804564:0.227356:0.804564:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515
9. :@0.076190:0.827427:0.089220:0.827427:0.089220:0.815152:0.076190:0.815152:0.006515:0.003257:0.003257
Meintjes G, :@0.101390:0.827427:0.168054:0.827427:0.168054:0.815152:0.101390:0.815152:0.010807:0.007644:0.002352:0.007173:0.003986:0.002387:0.007644:0.004563:0.003340:0.010254:0.003257:0.003257
et al.:@0.168148:0.827427:0.196758:0.827427:0.196758:0.815152:0.168148:0.815152:0.007644:0.003986:0.003340:0.008032:0.002352:0.003257
 Tuberculosis-associated immune reconstitution in-:@0.196758:0.827427:0.480932:0.827427:0.480932:0.815152:0.196758:0.815152:0.003340:0.005009:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003904:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.003351:0.002352:0.011030:0.011030:0.007150:0.007173:0.007644:0.003340:0.003540:0.007644:0.007608:0.007691:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.003340:0.002352:0.007173:0.003904
flammatory syndrome: Case definitions for use in resource-limited :@0.101390:0.838014:0.484213:0.838014:0.484213:0.825739:0.101390:0.825739:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.004786:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.004786:0.009560:0.008032:0.004563:0.007644:0.004798:0.008055:0.007644:0.002863:0.002863:0.007173:0.002352:0.003986:0.002352:0.007702:0.007161:0.004563:0.004798:0.003692:0.007702:0.003540:0.004786:0.007150:0.004563:0.007644:0.004798:0.002352:0.007173:0.004798:0.003540:0.007644:0.004563:0.007702:0.007150:0.003540:0.007608:0.007644:0.003904:0.002352:0.002352:0.011030:0.002352:0.003986:0.007644:0.008055:0.003257
settings. :@0.101390:0.848601:0.150086:0.848601:0.150086:0.836326:0.101390:0.836326:0.004563:0.007644:0.003986:0.003986:0.002352:0.007173:0.007914:0.004563:0.003257:0.003257
Lancet Infect Dis:@0.150086:0.848601:0.244900:0.848601:0.244900:0.836326:0.150086:0.836326:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257:0.002658:0.007173:0.003692:0.007644:0.007608:0.003986:0.003257:0.008749:0.002352:0.004563
. 2008; 8:516-23:@0.244889:0.848601:0.330225:0.848601:0.330225:0.836326:0.244889:0.836326:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515
10.  Bana T, :@0.076190:0.859189:0.147063:0.859189:0.147063:0.846913:0.076190:0.846913:0.006515:0.006515:0.003257:0.003257:0.005656:0.006750:0.008032:0.007173:0.008032:0.004163:0.005009:0.003257:0.003257
et al:@0.147957:0.859189:0.174121:0.859189:0.174121:0.846913:0.147957:0.846913:0.007644:0.003986:0.004151:0.008032:0.002352
. prolonged tuberculosis-associated immune reconsti-:@0.174121:0.859189:0.480967:0.859189:0.480967:0.846913:0.174121:0.846913:0.003257:0.004163:0.006961:0.003540:0.007702:0.002352:0.007702:0.007173:0.007914:0.007644:0.008055:0.004151:0.003986:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003904:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.004163:0.002352:0.011030:0.011030:0.007150:0.007173:0.007644:0.004151:0.003540:0.007644:0.007608:0.007702:0.007173:0.004563:0.003986:0.002352:0.003904
tution inflammatory syndrome: Characteristics and risk factors. :@0.101390:0.869776:0.454321:0.869776:0.454321:0.857500:0.101390:0.857500:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.002763:0.002352:0.007173:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.002775:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.002775:0.009560:0.007173:0.008032:0.003540:0.008032:0.007608:0.003986:0.007644:0.003540:0.002352:0.004563:0.003986:0.002352:0.007608:0.004563:0.002775:0.008032:0.007173:0.008055:0.002775:0.003540:0.002352:0.004563:0.005903:0.002775:0.003692:0.008032:0.007608:0.003986:0.007702:0.003540:0.004563:0.003257:0.003257
BMC :@0.453839:0.869776:0.484213:0.869776:0.484213:0.857500:0.453839:0.857500:0.006750:0.010807:0.009560:0.003257
Infect Dis:@0.101390:0.880363:0.153072:0.880363:0.153072:0.868087:0.101390:0.868087:0.002658:0.007173:0.003692:0.007644:0.007608:0.003986:0.003257:0.008749:0.002352:0.004563
. 2016;16:518:@0.153072:0.880363:0.224733:0.880363:0.224733:0.868087:0.153072:0.868087:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515
11.  Marais s, :@0.076190:0.890950:0.155318:0.890950:0.155318:0.878675:0.076190:0.878675:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.008032:0.003540:0.008032:0.002352:0.004563:0.004233:0.005856:0.003257:0.003257
et al.:@0.156294:0.890950:0.185787:0.890950:0.185787:0.878675:0.156294:0.878675:0.007644:0.003986:0.004222:0.008032:0.002352:0.003257
 Frequency, severity, and prediction of tuberculous :@0.185787:0.890950:0.484225:0.890950:0.484225:0.878675:0.185787:0.878675:0.004233:0.005703:0.003540:0.007644:0.008020:0.007150:0.007644:0.007173:0.007608:0.006303:0.003257:0.004222:0.004563:0.007644:0.006515:0.007644:0.003540:0.002352:0.003986:0.006303:0.003257:0.004233:0.008032:0.007173:0.008055:0.004233:0.008020:0.003540:0.007644:0.008055:0.002352:0.007608:0.003986:0.002352:0.007702:0.007173:0.004233:0.007702:0.003692:0.004233:0.003986:0.007150:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.007150:0.004563:0.003257
meningitis  immune  reconstitution  inflammatory  syndrome. :@0.101390:0.901537:0.438893:0.901537:0.438893:0.889262:0.101390:0.889262:0.011030:0.007644:0.007173:0.002352:0.007173:0.007914:0.002352:0.003986:0.002352:0.004563:0.003257:0.001811:0.002352:0.011030:0.011030:0.007150:0.007173:0.007644:0.003257:0.001811:0.003540:0.007644:0.007608:0.007702:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.003257:0.001799:0.002352:0.007173:0.002852:0.002852:0.008032:0.011030:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.003257:0.001811:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.003257
Clin In-:@0.440704:0.901537:0.480944:0.901537:0.480944:0.889262:0.440704:0.889262:0.009560:0.002352:0.002352:0.007173:0.005068:0.002658:0.007173:0.003904
fect Dis:@0.101390:0.912124:0.143242:0.912124:0.143242:0.899849:0.101390:0.899849:0.003692:0.007644:0.007608:0.003986:0.003257:0.008749:0.002352:0.004563
. 2013; 56(3):450-60.:@0.143242:0.912124:0.253543:0.912124:0.253543:0.899849:0.143242:0.899849:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
12.  Shelburne SA, Montes M, Hammill RJ. Immune reconstitution inflam:@0.076190:0.922963:0.477075:0.922963:0.477075:0.910688:0.076190:0.910688:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.007173:0.007644:0.002352:0.008020:0.007150:0.003540:0.007173:0.007644:0.003281:0.005856:0.008702:0.003257:0.003281:0.010807:0.007702:0.007173:0.003986:0.007644:0.004563:0.003281:0.010807:0.003257:0.003281:0.008032:0.008032:0.011030:0.011030:0.002352:0.002352:0.002352:0.003293:0.007138:0.005668:0.003257:0.003281:0.002658:0.011030:0.011030:0.007150:0.007173:0.007644:0.003281:0.003540:0.007644:0.007608:0.007702:0.007173:0.004563:0.003986:0.002352:0.003986:0.007150:0.003986:0.002352:0.007702:0.007173:0.003269:0.002352:0.007173:0.002852:0.002852:0.008032:0.011030
-:@0.477075:0.922963:0.480979:0.922963:0.480979:0.910688:0.477075:0.910688:0.003904
matory  syndrome:  More  answers,  more  questions. :@0.101390:0.933802:0.402639:0.933802:0.402639:0.921526:0.101390:0.921526:0.011030:0.008032:0.003986:0.007702:0.003540:0.006303:0.003257:0.003457:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.003257:0.003457:0.010807:0.007702:0.003540:0.007644:0.003257:0.003457:0.008032:0.007173:0.004563:0.009772:0.007644:0.003540:0.004563:0.003257:0.003257:0.003457:0.011030:0.007702:0.003540:0.007644:0.003257:0.003457:0.008020:0.007150:0.007644:0.004563:0.003986:0.002352:0.007702:0.007173:0.004563:0.003257:0.003257
J  Antimicrob :@0.406108:0.933802:0.484213:0.933802:0.484213:0.921526:0.406108:0.921526:0.005668:0.003257:0.003457:0.008702:0.007173:0.003986:0.002352:0.011030:0.002352:0.007608:0.003540:0.007702:0.008020:0.003257
Chemother.:@0.101390:0.944640:0.170100:0.944640:0.170100:0.932365:0.101390:0.932365:0.009560:0.007173:0.007644:0.011030:0.007702:0.003986:0.007173:0.007644:0.003540:0.003257
 2006;57:167-70:@0.170088:0.944640:0.255425:0.944640:0.255425:0.932365:0.170088:0.932365:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515
13.  Jong E, :@0.519056:0.082284:0.588706:0.082284:0.588706:0.070008:0.519056:0.070008:0.006515:0.006515:0.003257:0.003257:0.005656:0.005668:0.007702:0.007173:0.007914:0.003175:0.006303:0.003257:0.003257
et al:@0.588635:0.082284:0.613835:0.082284:0.613835:0.070008:0.588635:0.070008:0.007644:0.003986:0.003187:0.008032:0.002352
. Consensus statement: Management of drug-induced :@0.613835:0.082284:0.927090:0.082284:0.927090:0.070008:0.613835:0.070008:0.003257:0.003187:0.009560:0.007702:0.007173:0.004563:0.007644:0.007173:0.004563:0.007150:0.004563:0.003187:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.003187:0.010807:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003175:0.007702:0.003692:0.003187:0.008055:0.003540:0.007150:0.007914:0.003904:0.002352:0.007173:0.008055:0.007150:0.007608:0.007644:0.008055:0.003257
liver injury in HIV-positive patients treated for TB. Available at: htt-:@0.544256:0.093185:0.923821:0.093185:0.923821:0.080910:0.544256:0.080910:0.002352:0.002352:0.006515:0.007644:0.003540:0.004586:0.002352:0.007173:0.002387:0.007150:0.003540:0.006303:0.004586:0.002352:0.007173:0.004586:0.008032:0.002658:0.008255:0.003904:0.008020:0.007702:0.004563:0.002352:0.003986:0.002352:0.006515:0.007644:0.004586:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.004586:0.003986:0.003540:0.007644:0.008032:0.003986:0.007644:0.008055:0.004574:0.003692:0.007702:0.003540:0.004574:0.005009:0.006750:0.003257:0.004586:0.008702:0.006515:0.008032:0.002352:0.002352:0.008032:0.008020:0.002352:0.007644:0.004586:0.008032:0.003986:0.003257:0.004586:0.007173:0.003986:0.003986:0.003904
ps://sahivsoc.org/Files/Consensus%20statement_Management%20:@0.544256:0.104087:0.923891:0.104087:0.923891:0.091811:0.544256:0.091811:0.008032:0.004574:0.003269:0.005151:0.005151:0.004574:0.008043:0.007185:0.002364:0.006526:0.004574:0.007714:0.007620:0.003269:0.007714:0.003551:0.007926:0.005151:0.005715:0.002364:0.002364:0.007655:0.004574:0.005151:0.009572:0.007714:0.007185:0.004574:0.007655:0.007185:0.004574:0.007161:0.004574:0.009125:0.006526:0.006526:0.005868:0.003998:0.008043:0.003998:0.007655:0.011042:0.007655:0.007185:0.003998:0.005891:0.010819:0.008043:0.007185:0.008043:0.007926:0.007655:0.011042:0.007655:0.007185:0.003998:0.009125:0.006526:0.006515
of%20drug-induced%20liver%20injury%20in%20HIV%20positive%20:@0.544256:0.114988:0.923750:0.114988:0.923750:0.102713:0.544256:0.102713:0.007902:0.003892:0.009313:0.006715:0.006715:0.008255:0.003739:0.007350:0.008114:0.004104:0.002552:0.007373:0.008255:0.007350:0.007808:0.007843:0.008255:0.009313:0.006715:0.006715:0.002552:0.002552:0.006715:0.007843:0.003739:0.009313:0.006715:0.006715:0.002552:0.007373:0.002587:0.007350:0.003739:0.006503:0.009313:0.006715:0.006715:0.002552:0.007373:0.009313:0.006715:0.006715:0.008231:0.002857:0.008455:0.009313:0.006715:0.006715:0.008220:0.007902:0.004762:0.002552:0.004186:0.002552:0.006715:0.007843:0.009313:0.006715:0.006515
pts%20treated%20for%20TB%20(Oct%202013).pdf. Accessed Janu-:@0.544256:0.125890:0.923832:0.125890:0.923832:0.113614:0.544256:0.113614:0.008020:0.003986:0.004563:0.009113:0.006515:0.006515:0.003986:0.003540:0.007644:0.008032:0.003986:0.007644:0.008055:0.009113:0.006515:0.006515:0.003692:0.007702:0.003540:0.009113:0.006515:0.006515:0.005009:0.006750:0.009113:0.006515:0.006515:0.004339:0.010219:0.007608:0.003986:0.009113:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.008020:0.008055:0.003716:0.003257:0.005774:0.008702:0.007608:0.007608:0.007644:0.004563:0.004563:0.007644:0.008055:0.005774:0.005668:0.008032:0.007173:0.007150:0.003904
ary 2019.:@0.544256:0.136791:0.594703:0.136791:0.594703:0.124516:0.544256:0.124516:0.008032:0.003540:0.006303:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
14.  Meintjes G, :@0.519056:0.147693:0.611589:0.147693:0.611589:0.135417:0.519056:0.135417:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.007644:0.002352:0.007173:0.003986:0.002387:0.007644:0.004563:0.004010:0.010254:0.003257:0.003257
et al:@0.612353:0.147693:0.638377:0.147693:0.638377:0.135417:0.612353:0.135417:0.007644:0.003986:0.004010:0.008032:0.002352
. prednisone for the prevention of paradoxical tu-:@0.638377:0.147693:0.923821:0.147693:0.923821:0.135417:0.638377:0.135417:0.003257:0.004022:0.006961:0.003540:0.007644:0.008055:0.007173:0.002352:0.004563:0.007702:0.007173:0.007644:0.004010:0.003692:0.007702:0.003540:0.004010:0.003986:0.007173:0.007644:0.004010:0.008020:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.004010:0.007702:0.003692:0.004010:0.008020:0.008032:0.003540:0.008032:0.008055:0.007702:0.005644:0.002352:0.007608:0.008032:0.002352:0.004022:0.003986:0.007150:0.003904
berculosis-associated IRIs. :@0.544256:0.158594:0.694268:0.158594:0.694268:0.146319:0.544256:0.146319:0.008020:0.007644:0.003540:0.007608:0.007150:0.002352:0.007702:0.004563:0.002352:0.004563:0.003904:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.003257:0.002658:0.007138:0.002658:0.005856:0.003257:0.003257
NEJM:@0.694268:0.158594:0.725748:0.158594:0.725748:0.146319:0.694268:0.146319:0.008702:0.006303:0.005668:0.010807
 2018; 379:1915-25:@0.725748:0.158594:0.827371:0.158594:0.827371:0.146319:0.725748:0.146319:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515